home / stock / xyn / xyn news

XYN News and Press, Xynomic Pharmaceuticals Holdings Inc.

Stock Information
Company Name: Xynomic Pharmaceuticals Holdings Inc.
Stock Symbol: XYN
Market: NYSE
Menu
XYN XYN Quote XYN Short XYN News XYN Articles XYN Message Board
Get XYN Alerts

News, Short Squeeze, Breakout and More Instantly...
XYN - Week In Review: China Biopharma Announces Nearly $3 Billion In Deals

Deals and Financings Vivo Capital, a US-China healthcare investment firm, has raised $1.28 billion for its ninth fund, bringing its assets under management to more than $4.3 billion. Vivo invests in all stages of healthcare companies, from start-up to publicly owned. Founded in 1996, Vivo ...
XYN - Xynomic Completes Pre-IND Meeting with US FDA for XP-102, a Novel Pan-RAF Inhibitor against Colorectal Cancer and Lung Cancer

RALEIGH, N.C. and SHANGHAI, June 12, 2019 (GLOBE NEWSWIRE) --  Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, Nasdaq: XYN), a clinical stage US-China oncology drug development company, announced that it recently held a pre-IND meeting with the U.S. Food and Drug Admin...

XYN - Microcaps dominate midday movers

Gainers:  Provention Bio (NASDAQ: PRVB ) +296% . Vuzix Corporation (NASDAQ: VUZI ) +54% . Xynomic Pharmaceuticals Holdings (NASDAQ: XYN ) +46% . Tableau Software (NYSE: DATA ) +35% . Hi-Crush (NYSE: HCR ) +31% . Beyond Meat (NASDAQ: BYND ) +24% . Workhorse Group (NASDAQ: WKHS ) ...

XYN - Xynomic Dosed First Patient in Phase 1/2 Lymphoma Trial

RALEIGH, N.C. and SHANGHAI, June 06, 2019 (GLOBE NEWSWIRE) --  Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, Nasdaq: XYN), a clinical stage US-China oncology drug development company, announced that Xynomic has dosed the first patient in a Phase 1/2 trial that combin...
XYN - Xynomic Pharma To Present Long-Term Follow Up Data Showing Abexinostat, Combined with Pazopanib, has Durable Responses in Patients with Pre-Treated Kidney Cancer

RALEIGH, N.C. and SHANGHAI, May 21, 2019 (GLOBE NEWSWIRE) --  Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”), a clinical stage US-China oncology drug development company (Nasdaq: XYN), announced today that long-term follow up data of exceptional responders to abexinos...

Next 10